GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NanoString Technologies Inc (OTCPK:NSTGQ) » Definitions » Beneish M-Score

NanoString Technologies (NanoString Technologies) Beneish M-Score : -2.75 (As of Apr. 27, 2024)


View and export this data going back to 2013. Start your Free Trial

What is NanoString Technologies Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.75 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for NanoString Technologies's Beneish M-Score or its related term are showing as below:

NSTGQ' s Beneish M-Score Range Over the Past 10 Years
Min: -4.05   Med: -2.6   Max: -1.45
Current: -2.75

During the past 13 years, the highest Beneish M-Score of NanoString Technologies was -1.45. The lowest was -4.05. And the median was -2.60.


NanoString Technologies Beneish M-Score Historical Data

The historical data trend for NanoString Technologies's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NanoString Technologies Beneish M-Score Chart

NanoString Technologies Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.37 -1.45 -2.51 -2.11 -3.17

NanoString Technologies Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.10 -3.17 -2.81 -2.65 -2.75

Competitive Comparison of NanoString Technologies's Beneish M-Score

For the Medical Instruments & Supplies subindustry, NanoString Technologies's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NanoString Technologies's Beneish M-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, NanoString Technologies's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where NanoString Technologies's Beneish M-Score falls into.



NanoString Technologies Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of NanoString Technologies for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.4763+0.528 * 1.467+0.404 * 0.8227+0.892 * 1.2009+0.115 * 0.5213
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.9068+4.679 * -0.182569-0.327 * 1.5033
=-2.75

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep23) TTM:Last Year (Sep22) TTM:
Total Receivables was $48.4 Mil.
Revenue was 48.089 + 44.157 + 35.805 + 34.422 = $162.5 Mil.
Gross Profit was 17.403 + 14.4 + 12.934 + 13.3 = $58.0 Mil.
Total Current Assets was $211.8 Mil.
Total Assets was $274.7 Mil.
Property, Plant and Equipment(Net PPE) was $59.4 Mil.
Depreciation, Depletion and Amortization(DDA) was $14.4 Mil.
Selling, General, & Admin. Expense(SGA) was $150.1 Mil.
Total Current Liabilities was $77.5 Mil.
Long-Term Debt & Capital Lease Obligation was $242.1 Mil.
Net Income was -37.411 + -43.668 + -41.238 + -44.114 = $-166.4 Mil.
Non Operating Income was -0.451 + -0.211 + -0.007 + -0.631 = $-1.3 Mil.
Cash Flow from Operations was -19.699 + -31.448 + -35.749 + -28.081 = $-115.0 Mil.
Total Receivables was $27.3 Mil.
Revenue was 29.541 + 32.219 + 31.08 + 42.455 = $135.3 Mil.
Gross Profit was 15.818 + 16.367 + 16.302 + 22.409 = $70.9 Mil.
Total Current Assets was $318.7 Mil.
Total Assets was $383.6 Mil.
Property, Plant and Equipment(Net PPE) was $59.0 Mil.
Depreciation, Depletion and Amortization(DDA) was $6.7 Mil.
Selling, General, & Admin. Expense(SGA) was $137.8 Mil.
Total Current Liabilities was $50.9 Mil.
Long-Term Debt & Capital Lease Obligation was $246.0 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(48.352 / 162.473) / (27.273 / 135.295)
=0.2976 / 0.201582
=1.4763

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(70.896 / 135.295) / (58.037 / 162.473)
=0.52401 / 0.35721
=1.467

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (211.807 + 59.411) / 274.713) / (1 - (318.708 + 58.96) / 383.6)
=0.012722 / 0.015464
=0.8227

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=162.473 / 135.295
=1.2009

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(6.675 / (6.675 + 58.96)) / (14.399 / (14.399 + 59.411))
=0.101699 / 0.195082
=0.5213

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(150.092 / 162.473) / (137.83 / 135.295)
=0.923797 / 1.018737
=0.9068

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((242.124 + 77.532) / 274.713) / ((245.976 + 50.939) / 383.6)
=1.1636 / 0.774022
=1.5033

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-166.431 - -1.3 - -114.977) / 274.713
=-0.182569

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

NanoString Technologies has a M-score of -2.75 suggests that the company is unlikely to be a manipulator.


NanoString Technologies Beneish M-Score Related Terms

Thank you for viewing the detailed overview of NanoString Technologies's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


NanoString Technologies (NanoString Technologies) Business Description

Traded in Other Exchanges
Address
530 Fairview Avenue North, Seattle, WA, USA, 98109
NanoString Technologies Inc is engaged in the development, manufacturing and commercialization of instruments, consumables, and services for efficiently profiling the activity of hundreds of genes and proteins simultaneously from a single tissue sample. Its core technology includes proprietary chemistries that enable the labeling and counting of single molecules. The firm uses its technology to develop tools for scientific and clinical research, primarily in the fields of genomics and proteomics. It offers two product platforms such as nCounter Analysis System or nCounter, and GeoMx Digital Spatial Profiler or DSP system both include instruments, related consumables, and software. NanoString Technologies generates revenue from the sale of products and related services and collaborations.
Executives
Jonathan Todd Garland officer: Chief Commercial Officer C/O CYTEK BIOSCIENCES, INC., 47215 LAKEVIEW BOULEVARD, FREMONT CA 94538
K Thomas Bailey officer: Chief Financial Officer 1618 STATION STREET, VANCOUVER A1 V6A 1B6
R Bradley Gray director, officer: President and CEO 530 FAIRVIEW AVENUE NORTH, SUITE 2000, SEATTLE WA 98109
William Young director 14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
Waite Charles P Jr director, 10 percent owner 11023 NE 116TH STREET, KIRKLAND WA 98034
Gregory Norden director 16640 CHESTERFIELD GROVE DRIVE, SUITE 200, CHESTERFIELD MO 63005
Elisha W Finney director C/O VARIAN MEDICAL SYSTEMS, INC, 3100 HANSEN WAY M/S E-327, PALO ALTO CA 94304
Teresa M. Foy director 530 FAIRVIEW AVENUE NORTH, SEATTLE WA 98109
Joseph M Beechem officer: SVP, Research & Development 530 FAIRVIEW AVENUE NORTH, SUITE 2000, SEATTLE WA 98109
John D. Gerace officer: Chief Commercial Officer C/O NANOSTRING TECHNOLOGIES, INC., 530 FAIRVIEW AVENUE NORTH, SEATTLE WA 98109
Kirk Malloy director 5200 ILLUMINA WAY, SAN DIEGO CA 92122
J. Chad Brown officer: SVP, Sales & Marketing 530 FAIRVIEW AVENUE NORTH, SEATTLE WA 98109
Robert Hershberg director 3005 FIRST AVENUE, SEATTLE WA 98121
Janet George director 530 FAIRVIEW AVENUE NORTH, SEATTLE WA 98109
Dana E. Rollison director 530 FAIRVIEW AVENUE NORTH, SEATTLE WA 98109